Associations - daunorubicin

No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2	cytarabine + daunorubicin Sensitive: A2 - Guideline cytarabine + daunorubicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2
No biomarker	T Acute Lymphoblastic Leukemia	No biomarker	T Acute Lymphoblastic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase + nelarabine Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2	vincristine + prednisone + daunorubicin + pegaspargase Sensitive: A2 - Guideline vincristine + prednisone + daunorubicin + pegaspargase Sensitive : A2
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3
ARNT expression	Acute Myelogenous Leukemia	ARNT expression	Acute Myelogenous Leukemia	daunorubicin Resistant: C3 – Early Trials daunorubicin Resistant : C3	daunorubicin Resistant: C3 – Early Trials daunorubicin Resistant : C3
Chr inv(16)(p13;q22)/ CBFB-MYH11 fusion	Acute Myelogenous Leukemia	Chr inv(16)(p13;q22)/ CBFB-MYH11 fusion	Acute Myelogenous Leukemia	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4
RANBP2-ALK fusion	Chronic Myelomonocytic Leukemia	RANBP2-ALK fusion	Chronic Myelomonocytic Leukemia	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4
KRAS G12D + DNMT3A C559fsX	Sarcoma	KRAS G12D + DNMT3A C559fsX	Sarcoma	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4
KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
NGFR expression	Glioblastoma	NGFR expression	Glioblastoma	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D
LIFR expression	Glioblastoma	LIFR expression	Glioblastoma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
HK2 overexpression	Acute Myelogenous Leukemia	HK2 overexpression	Acute Myelogenous Leukemia	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D	daunorubicin Sensitive: D – Preclinical daunorubicin Sensitive : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D
TOP2A amplification	Rectal Cancer	TOP2A amplification	Rectal Cancer	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D	daunorubicin Resistant: D – Preclinical daunorubicin Resistant : D

daunorubicin

Associations
(20)

Associations
(20)

daunorubicin

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)